306 related articles for article (PubMed ID: 22547203)
1. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?
Stohl W
Curr Rheumatol Rep; 2012 Aug; 14(4):303-9. PubMed ID: 22547203
[TBL] [Abstract][Full Text] [Related]
2. The rationale for BAFF inhibition in systemic lupus erythematosus.
Davidson A
Curr Rheumatol Rep; 2012 Aug; 14(4):295-302. PubMed ID: 22535567
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
Stohl W
Expert Rev Clin Immunol; 2017 Jun; 13(6):623-633. PubMed ID: 28164726
[TBL] [Abstract][Full Text] [Related]
4. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
5. Belimumab and the clinical data.
Shum K; Askanase A
Curr Rheumatol Rep; 2012 Aug; 14(4):310-7. PubMed ID: 22614721
[TBL] [Abstract][Full Text] [Related]
6. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Espinosa G; Cervera R
Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
[TBL] [Abstract][Full Text] [Related]
7. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
[TBL] [Abstract][Full Text] [Related]
8. BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.
Fairfax K; Mackay IR; Mackay F
IUBMB Life; 2012 Jul; 64(7):595-602. PubMed ID: 22641424
[TBL] [Abstract][Full Text] [Related]
9. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
Wiglesworth AK; Ennis KM; Kockler DR
Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
[TBL] [Abstract][Full Text] [Related]
10. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
11. Targeting BLyS in systemic lupus erythematosus.
Liu Y; La Cava A
Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):91-6. PubMed ID: 22216778
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
Poh YJ; Baptista B; D'Cruz DP
Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
[TBL] [Abstract][Full Text] [Related]
14. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
15. The discovery and development of belimumab: the anti-BLyS-lupus connection.
Stohl W; Hilbert DM
Nat Biotechnol; 2012 Jan; 30(1):69-77. PubMed ID: 22231104
[TBL] [Abstract][Full Text] [Related]
16. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.
Lenert A; Niewold TB; Lenert P
Drug Des Devel Ther; 2017; 11():747-757. PubMed ID: 28331294
[TBL] [Abstract][Full Text] [Related]
19. Targeting the BLyS-APRIL signaling pathway in SLE.
La Cava A
Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
[TBL] [Abstract][Full Text] [Related]
20. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
Mosak J; Furie R
Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]